


 Cite this: *RSC Adv.*, 2020, 10, 6790

# Simple and efficient synthesis of bicyclic enol-carbamates: access to brabantamides and their analogues†

 Ondrej Záborský,<sup>ID</sup>\*<sup>a</sup> Ľudmila Petrovičová,<sup>a</sup> Jana Doháňošová,<sup>b</sup> Ján Moncol<sup>ID</sup><sup>c</sup> and Róbert Fischer<sup>a</sup>

Received 19th December 2019

Accepted 28th January 2020

DOI: 10.1039/d0ra00796j

[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

A novel synthetic approach towards the formation of the unusual bicyclic enol-carbamates, as found in brabantamides A–C, is reported. The bicyclic oxazolidinone framework was obtained in very good yield and with high *E/Z* selectivity from a readily available  $\beta$ -ketoester under mild reaction conditions using  $\text{Tf}_2\text{O}$  and 2-chloropyridine tandem. The major *E* isomer was used in the synthesis of the brabantamide A analogue.


Brabantamides A–C (**1–3**) (Fig. 1) were first isolated in 2000 from the culture extracts of *Pseudomonas fluorescens*.<sup>1</sup> They displayed nanomolar inhibitory activity towards lipoprotein-associated phospholipase A<sub>2</sub> (Lp-PLA<sub>2</sub>) and therefore they could be used in the treatment of the inflammatory diseases such as atherosclerosis.<sup>1–3</sup> It was found that the sugar moiety is not necessary for the biological activity against Lp-PLA<sub>2</sub>. In contrast, deglycosylated brabantamides A and C showed improved inhibitory activity compared to their natural counterparts.<sup>3</sup> Moreover, simplified brabantamide analogues with amide functional group and long alkyl side chains showed even higher inhibitory effect.<sup>4</sup> Brabantamides A–C also exhibit significant activity against Gram-positive bacteria, fungi, and oomycetes.<sup>5,6</sup> A recent study confirmed that the bicyclic scaffold and the long lipophilic side chain are essential for the antibacterial activity.<sup>7</sup>

Surprisingly, only five reports concerning the synthesis of the bicyclic oxazolidinone with an exocyclic double bond have been reported to date.

In 2000, Pinto *et al.* prepared a series of analogues of brabantamide A where the enol-carbamate **5** was first obtained by direct iodocyclization from acetylene derivative **4** and then converted into key ester **6** by carbonylation of the corresponding vinyl iodide in the presence of 2-(trimethylsilyl)ethanol and

$\text{PdCl}_2$  (Scheme 1a).<sup>4</sup> Another synthesis of the related esters **9** has been reported by Snider *et al.* in 2006, employing Wittig reaction between stabilized ylides and bicyclic oxazolidinone **8** synthesized from L-proline **7** (Scheme 1b).<sup>8</sup> Shortly after, bicyclic enol-carbamate **10** with an exocyclic methylene group was synthesized in one step from acetylene derivative **4** using gold(i) catalysts (Scheme 1c).<sup>9</sup> Very recently, Witte *et al.* reported the synthesis of series of *Z*-analogues of brabantamides **12** by cyclization of  $\beta$ -ketoamides **11** using CDI (Scheme 1d).<sup>7</sup> As a part of our ongoing research program aimed at the utilization of trifluoromethanesulfonic anhydride ( $\text{Tf}_2\text{O}$ )/2-halopyridine (2-XPy) tandem in the synthesis of bioactive natural products and their analogues, we envisioned that similar reaction conditions could be effectively used to form the bicyclic oxazolidinone framework as found in brabantamides.

The combination of  $\text{Tf}_2\text{O}$ /2-XPy was extensively and successfully used in the amide activation<sup>10,11</sup> as well as in generating isocyanate species from *N*-Boc and *N*-Cbz protected amines.<sup>12</sup> We anticipated that the *N*-Boc-protected  $\beta$ -ketoester **13** could react in its enolate form with *in situ* generated isocyanate ion by intramolecular 5-*endo-dig* cyclization to give bicyclic enol-cyclocarbamate **14** (Scheme 1e).


 Fig. 1 Structures of brabantamides A–C (**1–3**). Rha = rhamnose.

<sup>a</sup>Institute of Organic Chemistry, Catalysis and Petrochemistry, Slovak University of Technology in Bratislava, Radlinského 9, Bratislava, 81237, Slovak Republic. E-mail: [ondrej.zaborsky@stuba.sk](mailto:ondrej.zaborsky@stuba.sk)

<sup>b</sup>Central Laboratories, Slovak University of Technology in Bratislava, Radlinského 9, Bratislava, 81237, Slovak Republic


<sup>c</sup>Institute of Inorganic Chemistry, Technology and Materials, Slovak University of Technology in Bratislava, Radlinského 9, Bratislava, 81237, Slovak Republic

† Electronic supplementary information (ESI) available: Detailed experimental procedures, characterization, copies of <sup>1</sup>H, <sup>13</sup>C, COSY and HSQC NMR spectra of all compounds (PDF), and crystallographic data for **16a**, **20** and **21** (PDF and CIF). CCDC 1954308–1954310. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/d0ra00796j




At the start of our investigation, model  $\beta$ -ketoester **15**, prepared from *N*-Boc-L-proline,<sup>7</sup> was chosen as the model substrate to identify optimal reaction conditions (Table 1). According to Kokotos' protocol,<sup>12c</sup> the initial using of 1.5 equivalents of  $\text{TiF}_2\text{O}$  and 3 equivalents of 2-ClPy led to a full conversion of the substrate **15** in 15 minutes (monitored by TLC) (Table 1, entry 7). The inspection of  $^1\text{H}$  NMR spectrum of the crude reaction mixture confirmed the presence of only desired product **16** almost exclusively as *E* isomer (*E/Z* ratio 93 : 7) which was isolated in 53% combined yield. Gratifyingly, lowering the amount  $\text{TiF}_2\text{O}$  (1.1 equiv.) resulted in a significant increase of the yield up to 80% with the slight decrease of *E* isomer **16a** (Table 1, entry 8).<sup>13</sup> Any variation of the amount of 2-ClPy did not have any positive impact on the reaction (Table 1, entries 9 and 10). The use of other 2-halopyridines reduced yield of **16** and prolonged reaction times were observed (Table 1, entries 11–13). For comparison, when we applied Witte's reaction conditions, yield dropped remarkably and *E/Z* selectivity disappeared completely (Table 1, entry 14). At last, we tested other bases commonly used in the combination with  $\text{TiF}_2\text{O}$ . Triethylamine, 4-dimethylaminopyridine, pyridine, and 2,6-lutidine resulted only in traces of product **16** (Table 1, entries 2–5), as well as when no base was used (Table 1, entry 1). Using DBU, enol-carbamate **16** was formed in slightly improved *E/Z* ratio (Table 1, entry 6). Nevertheless,  $^1\text{H}$  NMR spectrum of the crude reaction mixture showed the formation of a large amount of unidentified by-products and desired product was isolated only in 41% yield.

**Table 1** Optimization of the reaction conditions for cyclization of  $\beta$ -ketoester **15**



Entry	$\text{TiF}_2\text{O}$	Base	Time (min)	<b>16a</b> : <b>16b</b> <sup>a</sup>	Yield <sup>b</sup> (%)
1	1.5	—	60	—	— <sup>c</sup>
2	1.5	$\text{Et}_3\text{N}$	60	—	— <sup>c</sup>
3	1.5	DMAP	60	—	— <sup>c</sup>
4	1.5	Pyridine	60	—	— <sup>c</sup>
5	1.5 <sup>d</sup>	2,6-Lutidine	60	—	— <sup>c</sup>
6	1.5 <sup>d</sup>	DBU	60	90 : 10	41 <sup>e,f</sup>
7	1.5	2-ClPy	15	93 : 7	53 <sup>e</sup>
8	1.1	2-ClPy	15	85 : 15	80 <sup>e</sup>
9	1.1	2-ClPy (1.5 equiv.)	40	85 : 15	75 <sup>e</sup>
10	1.1	2-ClPy (5 equiv.)	15	87 : 13	64 <sup>e</sup>
11	1.1	2-FPy	15	89 : 11	71 <sup>e</sup>
12	1.1	2-BrPy	70	86 : 14	73 <sup>e</sup>
13	1.1	2-IPy	90	86 : 14	68 <sup>e</sup>
14	Witte's protocol <sup>g</sup>		Overnight	50 : 50	36 <sup>e</sup>


<sup>a</sup> Ratio determined by  $^1\text{H}$  NMR of the crude reaction mixture. <sup>b</sup> Isolated combined yield. <sup>c</sup> Traces of products. <sup>d</sup> Reactions performed with 1.1 equiv. of  $\text{TiF}_2\text{O}$  did not lead to full conversion of ester **15**. <sup>e</sup> Reactions were performed on 1 mmol of ester **15**. <sup>f</sup> Reaction mixture contained a large amount of unidentified by-products. <sup>g</sup> Reaction conditions: (1)  $\text{TMSOTf}$  (2 equiv.),  $\text{CH}_2\text{Cl}_2$ , 0 °C, 1 h. (2) CDI (1.5 equiv.),  $\text{CH}_2\text{Cl}_2$ , 0 °C – rt, overnight.<sup>7</sup>



**Scheme 1** Literature syntheses of bicyclic enol-carbamates and method proposed herein.


It is noteworthy that the reaction can be performed on a gram scale without affecting the yield and both isomers are easily separable by FCC (see the ESI<sup>†</sup>).

The  $^1\text{H}$  and  $^{13}\text{C}$  NMR data of the major *E* isomer **16a** were consistent with those published previously.<sup>8</sup> Possible racemization in the course of the reaction was dismissed based on the comparing specific optical rotation with the published data for **16a** ( $[\alpha]_D^{22} = -261.1$  (*c* 1.01, MeOH); ref. 8:  $[\alpha]_D^{22} = -207$  (*c* 1.0, MeOH)). Most importantly, X-ray crystallographic analysis of **16a** (Fig. 2; see the ESI<sup>†</sup> for further details)<sup>14</sup> confirmed its absolute configuration on the C-7a carbon atom.



**Fig. 2** Molecular structure of the enol-carbamate *E*-**16a** confirmed by X-ray crystallographic analysis.






Scheme 2 Plausible mechanism of the cyclization  $\beta$ -ketoester **15**.

The minor *Z* isomer **16b** was isolated for the first time as the pure compound and was fully characterized. Its structure was assigned on the basis of its  $^1\text{H}$ ,  $^{13}\text{C}$ , COSY, HSQC, and HMBC NMR spectra.

A plausible mechanism of the cyclization of  $\beta$ -ketoester **15** was based upon previous works<sup>12a-c</sup> and it is depicted in Scheme 2. Isocyanate cation **II**, as a key intermediate, can be formed directly from iminium triflate **I** (path A) or through the formation of carbamoyl triflate **III** with subsequent elimination of triflate ion spontaneously (path B). Ester enolate moiety **IV** then reacts as *O*-



Scheme 3 Synthesis of the brabantamide A analogue **21**.




Fig. 3 Molecular structures of acid **20** (top) and amide **21** (bottom) confirmed by X-ray crystallographic analysis.

nucleophile *via* 5-*endo-dig* cyclization and leads predominantly to the formation of the enol-carbamate **16a**.

Next, the optimized conditions were briefly applied in the synthesis of the brabantamide A analogue **21** (Scheme 3). Starting  $\beta$ -ketoester **18** was synthesized in two steps in a 70% yield using both commercially available *N*-Boc-D-proline **17** and 2-(trimethylsilyl)ethanol. It ought to be mentioned that previously examined hydrolysis of the corresponding methyl ester **16a** under acidic as well as basic conditions failed due to the instability of the bicyclic enol-carbamate.<sup>3,8</sup>

Subsequent cyclization of ester **18** using optimized reaction conditions afforded enol-carbamate **19** in 76% yield as a mixture of *E* and *Z* isomers in a ratio of 89 : 11. After isolation of the major isomer *E*-**19a**, it was treated with TBAF, providing free acid **20** in 89% yield. Finally, an amidation of **20** with tetradecylamine in the presence of EDCI gave amide **21** in moderate 40% yield. Both free acid **20** and amide **21** were fully characterized for the first time and their structures were assigned on the basis of its  $^1\text{H}$ ,  $^{13}\text{C}$ , COSY, HSQC, and HMBC NMR spectra. Moreover, their structures were unambiguously confirmed by X-ray crystallographic analysis (Fig. 3; see ESI† for further details).<sup>14</sup>

## Conclusions

In conclusion, a new method of preparing bicyclic enol-carbamates with exocyclic double bond has been developed. Bicyclic oxazolidinone framework was obtained in one step from readily available  $\beta$ -ketoesters in very good yields and with high *E/Z* selectivity under mild reaction conditions using  $\text{Tf}_2\text{O}$  and 2-chloropyridine tandem. The simplicity of this method was exemplified by a short and effective synthesis of the analogue of brabantamide A from commercially available *N*-Boc-D-proline in five steps with an overall 17% yield.



## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

This work was supported by the Slovak Grant Agency for Science VEGA (project no. 1/0552/18) and the Research and Development Operational Programmes funded by the ERDF (ITMS project no. 26240120001 and 26240120025). This article was also created with the support of the MŠVVaŠ of the Slovak Republic within the Research and Development Operational Programme for the project “University Science Park of STU Bratislava” (ITMS project no. 26240220084) co-funded by the European Regional Development Fund.

## Notes and references

- 1 J. Thirkettle, E. Alvarez, H. Boyd, M. Brown, E. Diez, J. Hueso, S. Elson, M. Fulston, C. Gershater, M. L. Morata, P. Perez, S. Ready, J. M. Sanchez-Puelles, R. Sheridan, A. Stefanska and S. Warr, *J. Antibiot.*, 2000, **53**, 664.
- 2 D. J. Busby, R. C. B. Copley, J. A. Hueso, S. A. Readshaw and A. Rivera, *J. Antibiot.*, 2000, **53**, 670.
- 3 J. Thirkettle, *J. Antibiot.*, 2000, **53**, 733.
- 4 I. L. Pinto, H. F. Boyd and D. M. B. Hickey, *Bioorg. Med. Chem. Lett.*, 2000, **10**, 2015.
- 5 K. Reder-Christ, Y. Schmidt, M. Dörr, H.-G. Sahl, M. Josten, J. M. Raaijmakers, H. Gross and G. Bendas, *Biochim. Biophys. Acta*, 2012, **1818**, 566.
- 6 P. F. Andersson, J. Levenfors and A. Broberg, *BioControl*, 2012, **57**, 463.
- 7 P. Dockerty, J. G. Edens, M. B. Tol, D. Morales Angeles, A. Domenech, Y. Liu, A. K. H. Hirsch, J.-W. Veening, D.-J. Scheffers and M. D. Witte, *Org. Biomol. Chem.*, 2017, **15**, 894.
- 8 J. R. Duvall, F. Wu and B. B. Snider, *J. Org. Chem.*, 2006, **71**, 8579.
- 9 (a) A. Buzas and F. Gagosz, *Synlett*, 2006, **17**, 2727; (b) E.-S. Lee, H.-S. Yeom, J.-H. Hwang and S. Shin, *Eur. J. Org. Chem.*, 2007, 3503.
- 10 For reviews, see: (a) D. Kaiser and N. Maulide, *J. Org. Chem.*, 2016, **81**, 4421; (b) D. Kaiser, A. Bauer, M. Lemmerer and N. Maulide, *Chem. Soc. Rev.*, 2018, **47**, 7899.
- 11 For selected examples of the amide activation, see: (a) M. Movassaghi and M. D. Hill, *J. Am. Chem. Soc.*, 2006, **128**, 4592; (b) M. Movassaghi and M. D. Hill, *J. Am. Chem. Soc.*, 2006, **128**, 14254; (c) M. Movassaghi, M. D. Hill and O. K. Ahmad, *J. Am. Chem. Soc.*, 2007, **129**, 10096; (d) S.-L. Cui, J. Wang and Y.-G. Wang, *J. Am. Chem. Soc.*, 2008, **130**, 13526; (e) O. K. Ahmad, M. D. Hill and M. Movassaghi, *J. Org. Chem.*, 2009, **74**, 8460; (f) W. S. Bechara, G. Pelletier and A. B. Charette, *Nat. Chem.*, 2012, **4**, 228; (g) B. Peng, D. Geerdink, C. Farès and N. Maulide, *Angew. Chem., Int. Ed.*, 2014, **53**, 5462; (h) T. Wezeman, S. Zhong, M. Nieger and S. Bräse, *Angew. Chem., Int. Ed.*, 2016, **55**, 3823; (i) S. Shaaban, V. Tona, B. Peng and N. Maulide, *Angew. Chem., Int. Ed.*, 2017, **56**, 10938; (j) B. Mátravölgyi, T. Hergert, E. Bálint, P. Bagi and F. Faigl, *J. Org. Chem.*, 2018, **83**, 2282; (k) H. Chen, J.-L. Ye and P.-Q. Huang, *Org. Chem. Front.*, 2018, **5**, 943; (l) Y.-H. Huang, S.-R. Wang, D.-P. Wu and P.-Q. Huang, *Org. Lett.*, 2019, **21**, 1681; (m) T.-T. Chen, A.-E. Wang and P.-Q. Huang, *Org. Lett.*, 2019, **21**, 3808; (n) J. Li, M. Berger, W. Zawodny, M. Simaan and N. Maulide, *Chem*, 2019, **5**, 1883; (o) J. Li, R. Oost, B. Maryasin, L. González and N. Maulide, *Nat. Chem.*, 2019, **10**, 2327.
- 12 (a) S. Hwang, D. Kim and S. Kim, *Chem.–Eur. J.*, 2012, **18**, 9977; (b) J. In, S. Hwang, C. Kim, J. H. Seo and S. Kim, *Eur. J. Org. Chem.*, 2013, 965; (c) C. Spyropoulos and C. G. Kokotos, *J. Org. Chem.*, 2014, **79**, 4477; (d) H.-K. Kim and A. Lee, *Tetrahedron Lett.*, 2016, **57**, 4890; (e) H.-K. Kim and A. Lee, *Org. Biomol. Chem.*, 2016, **14**, 7345; (f) P. Bana, Á. Lakó, N. Z. Kiss, Z. Béni, Á. Szigetvári, J. Kóti, G. I. Túrós, J. Éles and I. Greiner, *Org. Process Res. Dev.*, 2017, **21**, 611; (g) A. Sevšek, L. Šrot, J. Rihter, M. Čelan, L. Q. van Ufford, E. E. Moret, N. I. Martin and R. J. Pieters, *ChemMedChem*, 2017, **12**, 483; (h) H. Valkenier, C. M. Dias, C. P. Butts and A. P. Davis, *Tetrahedron*, 2017, **73**, 4955; (i) G. Pandey, R. Fernandes and D. Dey, *Synlett*, 2018, **29**, 805; (j) G. Pandey, R. Fernandes, D. Dey and B. Majumder, *Tetrahedron*, 2018, **74**, 5752; (k) W. M. Abdelmagid, T. Adak, J. O. Freeman and M. E. Tanner, *Biochemistry*, 2018, **57**, 5591; (l) S. N. Ramachandra, C. Srinivasulu, B. Hosamani, S. L. and V. V. Sureshbabu, *ChemistrySelect*, 2018, **3**, 12089; (m) S. Hirasawa, K. Mukai, S. Sakai, S. Wakamori, T. Hasegawa, K. Souma, N. Kanomata, N. Ogawa, M. Aizawa and M. Emoto, *J. Org. Chem.*, 2018, **83**, 14457.
- 13 Lowering the temperature to 0 °C and –20 °C did not have any impact on the outcome of the reaction.
- 14 CCDC no. 1954308 (**16a**), 1954309 (**20**) and 1954310 (**21**) contain supplementary crystallographic data for this paper. All products were crystallized from the mixture of dichloromethane/*n*-hexanes as the solvents.

